MCID: END085
MIFTS: 44

Endometrial Serous Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Endometrial Serous Adenocarcinoma

MalaCards integrated aliases for Endometrial Serous Adenocarcinoma:

Name: Endometrial Serous Adenocarcinoma 12 15 17
Uterine Corpus Serous Adenocarcinoma 12
Uterine Papillary Serous Carcinoma 12
Uterine Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5750
NCIt 49 C27838
SNOMED-CT 67 722680009

Summaries for Endometrial Serous Adenocarcinoma

Disease Ontology : 12 A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia.

MalaCards based summary : Endometrial Serous Adenocarcinoma, also known as uterine corpus serous adenocarcinoma, is related to apocrine adenocarcinoma and estrogen excess. An important gene associated with Endometrial Serous Adenocarcinoma is MIR455 (MicroRNA 455), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Endometrial cancer. The drugs Letrozole and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include lymph node, uterus and breast, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Uterine serous carcinoma (USC), is an uncommon form of endometrial cancer that typically arises in... more...

Related Diseases for Endometrial Serous Adenocarcinoma

Diseases related to Endometrial Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 apocrine adenocarcinoma 30.5 TP53 PGR ERBB2
2 estrogen excess 30.5 PTEN PGR ELAPOR1
3 primary peritoneal carcinoma 30.2 TP53 PGR ERBB2 BRCA1
4 adenocarcinoma 30.1 TP53 PTEN POLE PIK3CA KRAS ERBB2
5 ovarian serous carcinoma 30.0 WT1 TP53 KRAS ERBB2
6 papillary serous adenocarcinoma 29.9 WT1 TP53 PGR KRAS BRCA1
7 endometrial hyperplasia 29.8 TP53 PTEN PGR KRAS ARID1A
8 in situ carcinoma 29.8 TP53 PTEN PIK3CA PGR ERBB2 BRCA1
9 endometrial adenocarcinoma 29.7 TP53 PTEN PGR KRAS ERBB2
10 papillary adenocarcinoma 29.7 TP53 PGR KRAS ERBB2 BRCA1
11 hereditary breast ovarian cancer syndrome 29.7 TP53 PTEN POLE KRAS ERBB2 BRCA1
12 gastrointestinal stromal tumor 29.6 WT1 TP53 PTEN KRAS ERBB2
13 lynch syndrome 29.2 TP53 PTEN POLE PIK3CA KRAS ERBB2
14 wilms tumor 1 29.2 WT1 TP53 PGR KRAS FBXW7 ERBB2
15 endometrioid ovary carcinoma 28.9 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
16 carcinosarcoma 28.6 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
17 serous cystadenocarcinoma 27.9 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
18 uterine carcinosarcoma 27.8 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
19 ovarian cancer 27.7 WT1 TP53 PTEN PIK3CA PGR MIR34B
20 endometrial cancer 26.7 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
21 rare head and neck tumor 10.5 TP53 PIK3CA
22 thyroid hurthle cell adenoma 10.5 PTEN PIK3CA
23 gastric papillary adenocarcinoma 10.5 TP53 ERBB2
24 clear cell adenofibroma 10.4 PPP2R1A PIK3CA ARID1A
25 breast juvenile papillomatosis 10.4 PIK3CA ERBB2
26 clear cell adenocarcinoma 10.4 TP53 PIK3CA ARID1A
27 familiar ovarian carcinoma 10.4 PIK3CA BRCA1
28 papillary carcinoma 10.4
29 polyploidy 10.4 TP53 AURKB
30 gallbladder adenocarcinoma 10.4 TP53 PIK3CA ERBB2
31 glassy cell carcinoma of the cervix 10.4 PGR ERBB2
32 fallopian tube carcinosarcoma 10.4 WT1 TP53
33 vulva cancer 10.4 TP53 PIK3CA ERBB2
34 bartholin's gland adenoma 10.4 TP53 PGR
35 bartholin's gland benign neoplasm 10.4 TP53 PGR
36 vestibular gland benign neoplasm 10.4 TP53 PGR
37 breast duct papilloma 10.4 PTEN PGR
38 parotid gland cancer 10.4 TP53 ERBB2
39 tetraploidy 10.4 BRCA1 AURKB
40 scirrhous adenocarcinoma 10.4 PGR ERBB2
41 endometrial squamous cell carcinoma 10.3 TP53 PGR
42 parameningeal embryonal rhabdomyosarcoma 10.3 TP53 PIK3CA FBXW7
43 brain stem glioma 10.3 TP53 PTEN PIK3CA
44 anal squamous cell carcinoma 10.3 TP53 PIK3CA FBXW7
45 epithelial-myoepithelial carcinoma 10.3 TP53 PIK3CA FBXW7
46 senile angioma 10.3 MIR455 CCNE1
47 breast scirrhous carcinoma 10.3 PGR ERBB2
48 oncocytic breast carcinoma 10.3 PGR ERBB2
49 adenofibroma 10.3 WT1 TP53 ARID1A
50 fallopian tube endometrioid adenocarcinoma 10.3 ERBB2 CCNE1 ARID1A

Graphical network of the top 20 diseases related to Endometrial Serous Adenocarcinoma:



Diseases related to Endometrial Serous Adenocarcinoma

Symptoms & Phenotypes for Endometrial Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.25 KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.25 KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.25 KRAS
4 Decreased viability GR00106-A-0 10.25 KRAS
5 Decreased viability GR00173-A 10.25 AURKB
6 Decreased viability GR00221-A-1 10.25 AURKB KRAS PIK3CA
7 Decreased viability GR00221-A-2 10.25 AURKB BRCA1 CDC42SE2 KRAS PIK3CA
8 Decreased viability GR00221-A-3 10.25 BRCA1
9 Decreased viability GR00221-A-4 10.25 AURKB CDC42SE2 PIK3CA
10 Decreased viability GR00249-S 10.25 AURKB CDC42SE2
11 Decreased viability GR00301-A 10.25 BRCA1 KRAS
12 Decreased viability GR00381-A-1 10.25 KRAS
13 Decreased viability GR00402-S-2 10.25 PIK3CA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-1 9.95 POLE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.95 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.95 POLE
17 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.95 BRCA1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.95 BRCA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.95 PTEN
20 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.95 PTEN
21 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.95 ERBB2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.95 ARID1A BRCA1 ERBB2 POLE PTEN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.95 ARID1A
24 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.95 ARID1A
25 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.95 ARID1A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.95 POLE
27 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.95 BRCA1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.95 ERBB2 POLE
29 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.95 BRCA1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.95 ARID1A
31 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.95 PTEN
32 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.95 KRAS
33 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.95 ERBB2 POLE
34 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.95 PTEN
35 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.95 ARID1A
36 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.95 ERBB2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.95 ERBB2 KRAS POLE PTEN
38 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.95 PTEN
39 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.95 ARID1A
40 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.95 ERBB2 POLE
41 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.95 ERBB2 POLE PTEN
42 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.95 POLE
43 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.95 PTEN
44 Decreased sensitivity to paclitaxel GR00112-A-0 9.26 PTEN WT1
45 Increased cell death in HCT116 cells GR00103-A-0 9.26 CHD4 FBXW7 PIK3CA PPP2R1A

MGI Mouse Phenotypes related to Endometrial Serous Adenocarcinoma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 ARID1A AURKB BRCA1 CCNE1 CHD4 ELAPOR1
2 cardiovascular system MP:0005385 10.38 ARID1A AURKB BRCA1 CCNE1 ELAPOR1 ERBB2
3 embryo MP:0005380 10.36 ARID1A AURKB BRCA1 CCNE1 CHD4 ERBB2
4 endocrine/exocrine gland MP:0005379 10.31 ARID1A BRCA1 CCNE1 CHD4 ERBB2 FBXW7
5 homeostasis/metabolism MP:0005376 10.31 ARID1A AURKB BRCA1 ELAPOR1 ERBB2 FBXW7
6 mortality/aging MP:0010768 10.31 ARID1A AURKB BRCA1 CCNE1 CHD4 ELAPOR1
7 growth/size/body region MP:0005378 10.3 ARID1A AURKB BRCA1 CCNE1 ERBB2 FBXW7
8 hematopoietic system MP:0005397 10.29 ARID1A BRCA1 CCNE1 CHD4 ELAPOR1 FBXW7
9 immune system MP:0005387 10.29 ARID1A BRCA1 CCNE1 CHD4 ELAPOR1 FBXW7
10 integument MP:0010771 10.2 AURKB BRCA1 CCNE1 ERBB2 FBXW7 KRAS
11 neoplasm MP:0002006 10.17 ARID1A AURKB BRCA1 CCNE1 ERBB2 FBXW7
12 muscle MP:0005369 10.02 ARID1A BRCA1 ERBB2 KRAS PGR PIK3CA
13 limbs/digits/tail MP:0005371 9.98 BRCA1 ELAPOR1 ERBB2 KRAS PGR PTEN
14 normal MP:0002873 9.9 ARID1A BRCA1 CCNE1 ERBB2 FBXW7 KRAS
15 no phenotypic analysis MP:0003012 9.86 ARID1A AURKB CHD4 KRAS PGR PIK3CA
16 reproductive system MP:0005389 9.77 ARID1A AURKB BRCA1 CCNE1 CLDN3 ELAPOR1
17 skeleton MP:0005390 9.32 ARID1A BRCA1 CCNE1 ELAPOR1 ERBB2 KRAS

Drugs & Therapeutics for Endometrial Serous Adenocarcinoma

Drugs for Endometrial Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
2
Everolimus Approved Phase 2, Phase 3 159351-69-6 70789204 6442177
3
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
4 Estrogens Phase 2, Phase 3
5 Hormone Antagonists Phase 2, Phase 3
6 Hormones Phase 2, Phase 3
7 Estrogen Antagonists Phase 2, Phase 3
8 Estrogen Receptor Antagonists Phase 2, Phase 3
9 Immunosuppressive Agents Phase 2, Phase 3
10 Immunologic Factors Phase 2, Phase 3
11 Aromatase Inhibitors Phase 2, Phase 3
12
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
13
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
14
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
15
afatinib Approved Phase 2 439081-18-2, 850140-72-6 10184653
16
leucovorin Approved Phase 2 58-05-9 6006 143
17
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
18
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
19
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
20
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
22
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
23 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
24 topoisomerase I inhibitors Phase 2
25 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
26 Protein Kinase Inhibitors Phase 2
27 Mitogens Phase 2
28 Vitamin B Complex Phase 2
29 Folate Phase 2
30 Vitamin B9 Phase 2
31 Albumin-Bound Paclitaxel Phase 1, Phase 2
32 Tubulin Modulators Phase 2
33 Antimitotic Agents Phase 2
34 Maytansine Phase 2
35 Analgesics, Non-Narcotic Phase 2
36 Cyclooxygenase 2 Inhibitors Phase 2
37 Analgesics Phase 2
38 Anti-Inflammatory Agents Phase 2
39 Cyclooxygenase Inhibitors Phase 2
40 Antirheumatic Agents Phase 2
41 Anti-Inflammatory Agents, Non-Steroidal Phase 2
42
Progesterone Approved, Vet_approved 57-83-0 5994

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
2 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
3 Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00022620 Phase 2 paclitaxel
4 A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
5 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
6 Prospective, Non-randomised Phase 2 Clinical Trial of Carboplatin Plus Paclitaxel With Sequential Radical Pelvic Radiotherapy for Uterine Serous Papillary Cancer Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
7 Phase II Trial- Weekly Taxotere and Topotecan for Recurrent Ovarian, Primary Peritoneal, Endometrial and Uterine Cancers Completed NCT00231855 Phase 2 Topotecan and Taxotere
8 Trial of Maintenance With Niraparib in Patients With Stage III, Stage IV or Platinum-sensitive Recurrent Uterine Serous Carcinoma Recruiting NCT04080284 Phase 2 Niraparib
9 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Recruiting NCT03668340 Phase 2 AZD1775
10 A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Active, not recruiting NCT02491099 Phase 2 Afatinib
11 A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer Not yet recruiting NCT03832361 Phase 2 IMGN853
12 A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin/Taxol Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma Not yet recruiting NCT04030000 Phase 1, Phase 2 Paclitaxel/Carboplatin
13 A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma Terminated NCT02112552 Phase 2 Paclitaxel;Carboplatin
14 A Pilot Phase II Trial of Celecoxib in Patients With Grade 2 or 3 Endometrioid-type, Clear Cell, and Papillary Serous Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
15 A Phase I Study of Stereotactic Body Radiation Therapy for Patients With Limited Locoregional Recurrences of Ovarian and Uterine Serous Carcinoma Recruiting NCT03325634 Phase 1
16 Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers Unknown status NCT02315469
17 The Role of Synuclein-gamma (SNCG) in the Carcinogenesis of Uterine Papillary Serous Carcinoma Not yet recruiting NCT01344837
18 Racial Disparity in Prevalence and Survival Rates in Endometrial Cancer Terminated NCT00375804

Search NIH Clinical Center for Endometrial Serous Adenocarcinoma

Genetic Tests for Endometrial Serous Adenocarcinoma

Anatomical Context for Endometrial Serous Adenocarcinoma

MalaCards organs/tissues related to Endometrial Serous Adenocarcinoma:

40
Lymph Node, Uterus, Breast, Brain, Thyroid, Testes, Cervix

Publications for Endometrial Serous Adenocarcinoma

Articles related to Endometrial Serous Adenocarcinoma:

(show top 50) (show all 223)
# Title Authors PMID Year
1
Superior vena cava syndrome associated with uterine serous carcinoma. 61
32577490 2020
2
Stage III uterine serous carcinoma: modern trends in multimodality treatment. 61
32266802 2020
3
Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report. 61
32300630 2020
4
Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report. 61
32215315 2020
5
A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy. 61
32067813 2020
6
Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression. 61
32258332 2020
7
Fallopian tube abnormalities in uterine serous carcinoma. 61
32409160 2020
8
Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. 61
32140533 2020
9
Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site. 61
31165997 2020
10
Adjuvant chemotherapy in endometrial cancer. 61
31950214 2020
11
Pathogenesis and Clinical Management of Uterine Serous Carcinoma. 61
32183290 2020
12
Distant recurrence in a patient with polyp-confined stage IA serous endometrial carcinoma treated with adjuvant chemotherapy: A case report and review of literature. 61
31890830 2020
13
Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. 61
31833974 2020
14
The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. 61
32190072 2020
15
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. 61
31839338 2020
16
Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma. 61
31815745 2020
17
Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus. 61
31560127 2020
18
Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. 61
31906456 2020
19
Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. 61
31739992 2020
20
Breast metastases: A rare manifestation of advanced uterine serous carcinoma. 61
31656850 2019
21
The role of omentectomy in the surgical treatment of uterine serous carcinoma. 61
31517308 2019
22
Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma. 61
31228268 2019
23
Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer. 61
31320996 2019
24
Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation. 61
30896884 2019
25
Synchronous renal and para-aortic metastasis in a uterine serous carcinoma: A case review and clinical considerations. 61
30740508 2019
26
Comparison of clinicopathologic and survival characteristics of high grade endometrial cancers; single center experience. 61
30122267 2019
27
Sectioning and extensively examining the fimbriated end (SEE-FIM) of the fallopian tube in routine practices, is it worth the effort? 61
30506766 2019
28
[Uterine serous carcinoma accompany with serous endometrial intraepithelial carcinoma and papillary proliferation of the endometrium: report of a case]. 61
30641649 2019
29
Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial. 61
30371562 2018
30
Hysterectomy at the time of risk-reducing surgery in BRCA carriers. 61
30364812 2018
31
Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management. 61
30613348 2018
32
Characterization of Risk Factors and Timing of Venous Thromboembolism in Patients With Uterine Serous Carcinoma. 61
30303906 2018
33
Aging and uterine serous carcinoma. 61
29565096 2018
34
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. 61
29941483 2018
35
BET inhibitors: Betting on improved outcomes in uterine serous carcinoma. 61
30464799 2018
36
Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel. 61
30174791 2018
37
Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it. 61
30265854 2018
38
Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. 61
29977989 2018
39
Successful multidisciplinary treatment of uterine serous carcinoma in a patient who had previously undergone renal transplantation. 61
30122587 2018
40
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. 61
29584549 2018
41
Prognostic Factors of Uterine Serous Carcinoma-A Multicenter Study. 61
29621127 2018
42
High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma. 61
29940909 2018
43
MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. 61
29518404 2018
44
Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy. 61
29533019 2018
45
Saddle pulmonary embolus resulting in cardiovascular collapse requiring extracorporeal membrane oxygenation in a postoperative patient with endometrial cancer. 61
29915795 2018
46
Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer. 61
29845102 2018
47
Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy. 61
29550183 2018
48
Malignant Endometrial Polyps in Uterine Serous Carcinoma: The Prognostic Value of Polyp Size and Lymphovascular Invasion. 61
29420362 2018
49
The impact of histological subtype in developing both ovarian and endometrial cancer: A longstanding nationwide incidence study. 61
29227847 2018
50
Synthetically lethal nanoparticles for treatment of endometrial cancer. 61
29203914 2018

Variations for Endometrial Serous Adenocarcinoma

Copy number variations for Endometrial Serous Adenocarcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 52344 11 16200000 21700000 Copy number SAA Uterine serous papillary cancer

Expression for Endometrial Serous Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Serous Adenocarcinoma.

Pathways for Endometrial Serous Adenocarcinoma

Pathways related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 TP53 PPP2R1A PIK3CA KRAS CLDN3 CCNE1
2
Show member pathways
12.86 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
3
Show member pathways
12.86 TP53 PTEN PPP2R1A CHD4 CCNE1 BRCA1
4 12.82 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
5
Show member pathways
12.75 TP53 PTEN PPP2R1A PIK3CA KRAS ERBB2
6
Show member pathways
12.71 TP53 PTEN PIK3CA KRAS ERBB2
7
Show member pathways
12.7 TP53 POLE FBXW7 CCNE1 BRCA1
8
Show member pathways
12.66 TP53 PTEN PPP2R1A PIK3CA KRAS ERBB2
9
Show member pathways
12.62 TP53 PTEN PIK3CA KRAS ERBB2
10
Show member pathways
12.51 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
11 12.5 TP53 PPP2R1A CCNE1 BRCA1 AURKB
12
Show member pathways
12.49 TP53 PTEN PIK3CA KRAS ERBB2
13
Show member pathways
12.43 TP53 PIK3CA KRAS ERBB2
14
Show member pathways
12.34 TP53 PTEN MIR34B CCNE1 BRCA1
15
Show member pathways
12.31 TP53 PTEN PIK3CA ERBB2
16
Show member pathways
12.31 PPP2R1A PIK3CA PGR KRAS CCNE1
17 12.3 TP53 PIK3CA KRAS ERBB2
18
Show member pathways
12.28 TP53 PTEN PIK3CA PGR KRAS ERBB2
19 12.27 TP53 PTEN PIK3CA KRAS CCNE1
20
Show member pathways
12.25 TP53 PTEN CCNE1 BRCA1
21 12.25 TP53 PTEN PIK3CA MIR34B KRAS ERBB2
22
Show member pathways
12.22 PGR FBXW7 CCNE1 BRCA1
23
Show member pathways
12.22 TP53 PTEN PIK3CA KRAS ERBB2
24 12.22 TP53 PIK3CA KRAS CHD4 CCNE1
25 12.14 TP53 PTEN KRAS BRCA1
26
Show member pathways
12.13 PTEN PIK3CA KRAS ERBB2
27 12.05 TP53 PTEN PIK3CA KRAS CCNE1
28 11.94 TP53 PTEN KRAS CCNE1
29
Show member pathways
11.92 PIK3CA PGR KRAS ERBB2
30 11.91 TP53 PTEN PPP2R1A PIK3CA KRAS
31 11.86 TP53 PTEN PIK3CA KRAS ERBB2
32 11.84 PTEN CCNE1 BRCA1
33 11.83 TP53 PTEN PIK3CA CCNE1
34 11.82 TP53 POLE CCNE1
35
Show member pathways
11.81 TP53 CCNE1 BRCA1
36 11.73 TP53 KRAS ERBB2
37 11.64 TP53 PIK3CA ERBB2 BRCA1
38 11.58 TP53 PTEN PIK3CA
39 11.56 TP53 PTEN PIK3CA KRAS ERBB2
40 11.54 TP53 MIR34B CCNE1
41 11.5 TP53 PTEN BRCA1
42 11.47 TP53 CCNE1 BRCA1
43 11.3 TP53 CCNE1 BRCA1
44 11.28 TP53 BRCA1 AURKB
45 11.26 PTEN PIK3CA KRAS
46 11.24 TP53 CCNE1 BRCA1
47 10.99 TP53 PTEN PIK3CA FBXW7 ERBB2 BRCA1
48 10.98 TP53 CCNE1 BRCA1
49 10.36 TP53 CCNE1

GO Terms for Endometrial Serous Adenocarcinoma

Cellular components related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 WT1 TP53 PTEN POLE PGR FBXW7
2 cytoplasm GO:0005737 9.5 WT1 TP53 PTEN PPP2R1A PIK3CA PGR

Biological processes related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.85 WT1 TP53 ERBB2 CHD4 BRCA1 ARID1A
2 heart development GO:0007507 9.62 WT1 TP53 PTEN ERBB2
3 phosphatidylinositol 3-kinase signaling GO:0014065 9.43 PTEN PIK3CA ERBB2
4 androgen receptor signaling pathway GO:0030521 9.33 CCNE1 BRCA1 ARID1A
5 regulation of signal transduction by p53 class mediator GO:1901796 9.26 TP53 CHD4 BRCA1 AURKB
6 positive regulation of gene expression GO:0010628 9.17 WT1 TP53 PTEN KRAS ERBB2 CLDN3

Molecular functions related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 TP53 PTEN PGR FBXW7 ERBB2 CLDN3
2 zinc ion binding GO:0008270 9.1 WT1 TP53 POLE PGR CHD4 BRCA1

Sources for Endometrial Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....